Literature DB >> 2676192

HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus.

D Trono1, M B Feinberg, D Baltimore.   

Abstract

The products of the human immunodeficiency virus (HIV) gag gene exist in a highly multimerized state in the mature virion. For that reason, they may represent a particularly suitable target for the generation of dominant negative mutants. A number of HIV site-directed Gag mutants did show interference with the production of infectious viral particles from cells in which they were cotransfected with a wild-type proviral DNA. Furthermore, cells constitutively expressing such HIV Gag mutants had an impaired ability to support HIV replication when infected with wild-type virus. The block was localized to the late stages of the virus life cycle. Such Gag variants could constitute prototypes for the development of anti-HIV intracellular immunization.

Entities:  

Mesh:

Year:  1989        PMID: 2676192     DOI: 10.1016/0092-8674(89)90874-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  117 in total

1.  Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73.

Authors:  B E Sawaya; K Khalili; J Gordon; A Srinivasan; M Richardson; J Rappaport; S Amini
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Matrix protein of Akv murine leukemia virus: genetic mapping of regions essential for particle formation.

Authors:  E C Jørgensen; F S Pedersen; P Jørgensen
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

4.  Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.

Authors:  L E Henderson; M A Bowers; R C Sowder; S A Serabyn; D G Johnson; J W Bess; L O Arthur; D K Bryant; C Fenselau
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization.

Authors:  Mireille Guyader; Etsuko Kiyokawa; Laurence Abrami; Priscilla Turelli; Didier Trono
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

7.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.

Authors:  Z Matsuda; X Yu; Q C Yu; T H Lee; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: requirement for a C-terminal domain.

Authors:  E J Platt; O K Haffar
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

10.  Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.

Authors:  C Aiken; D Trono
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.